19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction (CS-1000)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02035085|
Recruitment Status : Recruiting
First Posted : January 14, 2014
Last Update Posted : December 19, 2020
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: CS-1000 labeled SVF cells||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||This is a First-in-man, Phase I Study Utilizing 19F Magnetic Resonance Imaging (MRI) to Track Autologous, Adipose Derived Stem Cells.|
|Estimated Study Start Date :||December 2021|
|Estimated Primary Completion Date :||December 2023|
|Estimated Study Completion Date :||December 2023|
Breast cancer patients with RIF will undergo liposuction, the autologous SVF cell fraction will be isolated and labeled with CS-1000 in the operating room without entering cell culture, which will then be returned to the patient at the site of breast grafting.
Drug: CS-1000 labeled SVF cells
Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
- 19F MRI signal over time [ Time Frame: within 18 months ]The engraftment of transplanted cells will be tracked in ways not possible before, using the total fluorine signal as surrogate marker for cell persistence and survival.
- Maintenance of breast contour and volume [ Time Frame: within 18 months ]CTCAE/CTEP scale examination criteria (retraction, atrophy, breast and arm edema, ulceration, telangiectasia, and induration/fibrosis will be used for assessments.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02035085
|Contact: Jeff Bulte, PhDfirstname.lastname@example.org|
|Contact: Ricardo Rodriguez, MDemail@example.com|
|United States, Maryland|
|Lutherville-Timonium, Maryland, United States, 21093|
|Contact: Ricardo Rodriguez, MD 410-494-8100 firstname.lastname@example.org|
|Principal Investigator:||Jeff WM Bulte, PhD||Johns Hopkins University|
|Study Director:||Ricardo Rodriguez, MD||Cosmeticsurg.net|